8 results about "Ephedrine" patented technology

A compound, as shown in Formula I, is a multi-heterocyclic compound. It has been verified that the compound provided by this invention integrates a novel compound targeting the calcitonin gene-related peptide (CGRP) based on ephedrine. Upon contact with the skin, due to photoactivated cell biological function regulation and the blocking effect of the multi-heterocyclic compound I structure on serotonin receptors, it achieves therapeutic effects on cutaneous vascular malformations and telangiectasia, improves the effectiveness of phototherapy in improving chronic cutaneous vascular diseases, and promotes skin wound healing.

The application belongs to the technical field of water treatment, and particularly relates to a new psychoactive substance adsorbent and application thereof. The preparation method of the adsorbent comprises the following steps: (1) mixing and reacting activated shrimp shell biomass and ferroferric oxide nano magnetic material, drying, and pyrolyzing to obtain Fe3O4@BC; (2) mixing and reacting Fe3O4@BC and ZIF-8 to obtain Fe3O4@BC@ZIF-8; and (3) mixing and reacting a eutectic solvent with Fe3O4@BC@ZIF-8 to obtain the new psychoactive substance adsorbent. The adsorbent has strong adsorption capacity for 4-methyl methcathinone, methcathinone, amphetamine, methamphetamine and ephedrine, and the adsorption efficiency can reach 98% for 4-methyl methcathinone in particular.

This invention discloses the application of ephedrine in the preparation of drugs for the prevention or treatment of peritoneal fibrosis, relating to the field of biomedical technology. The key technical point is: a pharmaceutical preparation for the prevention or treatment of peritoneal fibrosis, the active ingredient of which is ephedrine. This pharmaceutical preparation can achieve preventive and therapeutic effects on peritoneal fibrosis by inhibiting the mesothelial metastatic process (MMT) in peritoneal mesothelial cells, downregulating the expression of fibrosis-related proteins, and improving peritoneal ultrafiltration and solute transport functions, thus providing a new drug option for the treatment of end-stage renal disease patients undergoing peritoneal dialysis.

The application discloses a liquid membrane for sewage treatment and a preparation method thereof. The liquid membrane comprises a emulsion formed by mixing vegetable oil, a surfactant, Gleditsia sinensis saponin and an aqueous inorganic acid solution. The preparation method of the emulsion membrane comprises the following steps: mixing the vegetable oil, the surfactant, the Gleditsia sinensis saponin and the aqueous inorganic acid solution according to proper proportions, and fully stirring to obtain stable emulsion. The emulsion membrane can be applied to treatment of sewage containing ephedrine. The application can efficiently recover and extract ephedrine from pharmaceutical wastewater, reduce the ephedrine content in the pharmaceutical wastewater, reduce the influence of ephedrine on the environment, improve the raw material utilization rate of ephedrine, and the recovery efficiency of ephedrine can reach more than 80%. The extraction and recovery steps of ephedrine are simple, time-consuming is short, and the application has a good industrial application prospect.

The invention relates to a method for extracting ephedrine E from herba ephedrae, which can effectively extract ephedrine E from herba ephedrae and realize application in preparation of medicines for treating pulmonary arterial hypertension. The preparation method comprises the following steps: taking dried roots and rhizomes of ephedra sinica stapf, extracting by adopting a water decoction method, concentrating under reduced pressure to obtain total extract, dispersing with water, eluting, dissolving with methanol, stirring with silica gel, carrying out gradient elution, identifying, merging the same fractions, loading a target component on column chromatography, eluting, purifying, collecting the fractions within retention time, and drying to obtain ephedrine E; the preparation method is simple, the ephedrine E is easy to industrially prepare, the medicinal value of ephedra is expanded, the application in preparation of the medicine for treating the pulmonary arterial hypertension is realized, and the ephedrine E is a great innovation in preparation of the medicine for treating the pulmonary arterial hypertension and has practical popularization and application value.

The application discloses a traditional Chinese medicine extract, which is made of traditional Chinese medicines including the following raw materials: Magnolia officinalis 1-100 parts, Strychnos ignatii 1-100 parts, Toddalia asiatica 1-100 parts, Ephedra 1-100 parts, Bitter almond 1-100 parts, Notopterygium 1-100 parts, Ginger 1-100 parts, Pogostemonis 1-100 parts, Pterocephalus 1-100 parts, Atractylodes 1-100 parts, Poria cocos 1-100 parts, Atractylodes 1-100 parts, Gypsum fibrosum 1-100 parts, Fritillaria cirrhosa 1-100 parts, Ficus 1-100 parts, Fagopyrum 1-100 parts, Earthworm 1-100 parts, Radix et Rhizoma Cynanchi 1-100 parts, Equisetum ramosissimum 1-100 parts, Lepidium apetalum 1-100 parts, wherein the extract contains ephedrine with a content of 0.5-1.5 mg / g, and the solid content transfer rate is 18-25%.

The invention discloses an inherited cough and asthma relieving compound medicine and a preparation method thereof. The medicine is prepared into various dosage forms such as granules, tablets and the like from 14 traditional Chinese medicines such as honey-fried ephedra, semen armeniacae amarae, lumbricus and the like through the processes of superfine grinding, gradient decoction, low-temperature drying and the like. The innovation points are as follows: (1) ephedra-earthworm synergistically relieve spasm, stiff silkworm-schisandra chinensis jointly regulate and control a calcium ion channel, and rapid cough relieving and long-acting asthma relieving are realized; (2) gradient decoction is combined with an inclusion technology, so that the dissolution rate of ephedrine is increased by 42%, and the retention rate of glycyrrhizic acid is greater than or equal to 78%; (3) an IL-6 / TNF-alpha inflammation pathway is inhibited at multiple targets, and the airway hyperreactivity is reduced; and (4) the granule D90 is less than or equal to 150 microns, the water content is less than or equal to 5%, and the dissolution rate reaches 90% or above. Clinical tests show that the total effective rate is 91.7%, the FEV1 improvement rate is improved by 41.7% compared with that of a single-formula control group, and the hormone dosage can be reduced by 30%. The preparation has the advantages of traditional cough treatment experience and modern pharmaceutical technology, and provides a safe and effective new choice for treatment of CVA.

The invention provides new application of rupestonic acid ephedrine ester in cancer treatment, in-vitro anti-tumor tests of rupestonic acid ephedrine ester accidentally find that rupestonic acid ephedrine ester has remarkable inhibitory activity on pancreatic cancer cells (PANC1), cervical cancer cells (Hela), ovarian cancer cells (A2780), lung cancer cells (A549) and liver cancer cells (Hep G-2), and can be used for preparing medicines for treating tumors.